Over the past few years, the biopharmaceutical industry has revved up efforts to diversify clinical trials. But clinical trials for rare diseases are still too often homogeneous. Rare disease experts at the Milken Institute Future of Health Summit on Tuesday had words of warning for biopharma: Don’t let equity efforts peter out.
Pharmaceutical companies can’t keep developing trials for rare disease treatments without solving for equity, said Tamar Thompson, head of corporate affairs at Alexion, AstraZeneca’s rare disease division. “We need to put this as a challenge to the CEOs and think about the environmental, social, and governance aspects of this as well.”
Create a display name to comment
This name will appear with your comment